Advertisement

The AMCP Managed Care & Specialty Pharmacy Annual Meeting is taking place March 25-29, 2019 in San Diego, California.  Individuals within managed care pharmacy and the industries that work with them will come together to learn, network and discuss the issues facing the health care system today.  A special pre-conference titled Specialty Connect will focus on gene therapy and explore payer considerations for supporting patient access to these innovative treatments.

This site features highlights throughout the event including both educational and poster presentations.

AMCP Annual Meeting 2019

On the Horizon: The Specialty Pharmacy Pipeline

Specialty medications represent about 1.5% to 2.5% of prescriptions but comprise approximately 50% of total prescription costs. The average cost of a specialty drug...

How to Manage Generics When They Become Too Costly

There is insufficient competition in the generic drug marketplace, and market consolidation has led to price increases. Because of a lack of appropriate alternatives...

Real-Time Benefit Checks May Improve Medication Adherence, Reduce Patient Costs

Providers often have a limited knowledge of a specific patient’s insurance coverage when prescribing medications, and a real-time benefit check program may be a...

Tips for Addressing the Medical Pharmacy Benefit Spend

A total of 49 specialty drugs were approved in 2018: 25 managed through the medical benefit, 19 through the pharmacy benefit, and...

Switching Biologics Is Costlier Among Patients With Psoriasis

A recent study assessed the costs associated with switching biologic agents for patients with psoriasis. The authors found that compared with persistent users, patients who...

Limiting Pharmaceutical Coupon Use Is More Cost-Effective

Coupons are commonly marketed to patients and prescribers to insulate patients from higher costs associated with brand-name drugs. However, these coupons can...

Session Puts a Spotlight on Health Care Disruptors and Innovators

Despite its rising level of health care spending, the United States lags behind other countries in many outcomes and quality measures. Much of the...

AMCP Headline Session: Trends and Development in Pharmaceuticals

During a presentation at the AMCP Annual Meeting, Douglas M. Long, BS, MBA, vice president of industry relations at Iqvia in Ponte Vedra...

How to Address the Drug Coupon Challenge

The number of drugs with copay cards has soared in the past 10 years, from 75 drugs in 2009 to 700 drugs...

Best Practices for Navigating Preapproval Information Exchange

Preapproval information exchange is the communication between biopharmaceutical companies and population health decision-makers on topics such as phase III clinical trial data, pharmacoeconomic data,...

What Is the Role of an Actuary on Pharmacy Benefits?

An actuary is a business professional who deals with the measurement and management of risk and uncertainty, particularly compiling and analyzing statistics to calculate...

The OIG’s Proposed Change to Rebates and the Effect on Stakeholders

Manufacturers and payers, including managed care organizations, have been entering into agreements to discount drug prices in exchange for formulary placement, volume commitments, and...

Specialty Drug Growth Continues: A Look at the Pipeline

Key specialty pharmaceuticals market trends include increased competition along with cancer and orphan drug development, according to Aimee Tharaldson, PharmD, senior clinical consultant of emerging...

How to Design and Implement Value-Based Contracts

Value-based contracts are written contractual agreements in which the payment terms for medications or other health care technologies are tied to agreed‐upon...

Regulatory Guidance on Biosimilar Development, Plus a Look at the Biosimilar Pipeline

Eighteen biosimilars have been licensed by the Food and Drug Administration (FDA) since 2015, seven of which have launched. When submitting a...

Health Care Legislation: What’s to Come?

Health care remains a hot political issue, and it was ranked the top concern among voters in the 2018 midterm elections. With a...

How Will the U.S. Pay for Gene Therapies?

Gene therapy involves introducing genetic material into cells to compensate for abnormal genes or to make a beneficial protein. However, this is a very...

Payer and Manufacturer Perspectives for Agreeing on Value-Based Contracts in Medicaid

The need for value-based contracts for Medicaid plans has grown as a response to increasing prescription drug spending, more costly specialty medications, and finite...

Introduction to Gene Therapy: What Is It and How Do We Pay for It?

According to the American Society of Gene and Cell Therapy, gene therapy is “the introduction, removal, or change in the content of...

A Look at the Gene Therapy Pipeline

Gene therapy is a technique that modifies a person’s genes to treat or cure disease through several mechanisms that can include replacing a disease-causing...

Study Finds Split-Fill Option for Oral Oncology Medication Is Beneficial

A “split-fill” pharmacy option, which dispenses medications at half-quantity intervals, seeks to reduce pharmacy costs and medication wastage due to early treatment discontinuation.

Biologic Switching Increases Health Care Costs Among Patients With Ankylosing Spondylitis and PsA

Switching from one biologic agent to another can have cost implications for payers and patients, but there is limited information on switching rates among...

Deprescribing Diabetes Medications Reduces Risk of Hypoglycemia, Mortality

Deprescribing medication is the planned and supervised process of dose reduction of therapy that is no longer beneficial or may cause harm. However, there...

Exclusion Formulary Results in Pharmacy Savings

An exclusion formulary places certain medications within a drug class that have clinically supported alternatives in a noncoverage status in an effort to address...
Advertisement